Navigation Links
Silence Therapeutics Announces Positive Outcome From Oral Hearing at the European Patent Office
Date:12/7/2011

LONDON, December 7, 2011 /PRNewswire/ --

Silence Therapeutics plc (AIM: SLN) ("Silence" or the "Company"), a leading RNA interference (RNAi) therapeutics company, announces a positive outcome from the oral hearing on 6 December 2011 at the European Patent Office (EPO) over opposition to Silence's granted European Patent EP 1 536 827 "Further use of protein kinase N beta".

The granted patent refers to the gene target PKN3, protein kinase N beta, targeted by Silence's lead program Atu027, which is currently in a Phase I clinical study. The Opposition division of the EPO decided to uphold the patent in amended form.

Claim one of the patent relates to the use of protein kinase N beta as a downstream target of the PI3 kinase pathway. Claim two relates to the use of protein kinase N beta as a downstream drug target of the PI3 kinase pathway in a screening process. Both of these claims are maintained as granted, and also the use claims where manufacture of a diagnostic agent is based on use of protein kinase N beta as such (or use of antibodies, spiegelmers, aptamers, ribozymes, antisense molecules and siRNA molecules directed against protein kinase N beta and the nucleic acid molecule coding for these, respectively).

In connection with the use claims where protein kinase N beta as such (or antibodies, spiegelmers, aptamers, ribozymes, antisense molecules and siRNA molecules directed against protein kinase N beta and the nucleic acid molecule coding therefore, respectively) are used for the manufacture of a medicament, the diseases for which such medicament is to be used are now restricted to metastatic cancers. This is the focus of Silence's currently ongoing Atu027 Phase I study with late-stage cancer patients.

Commenting on today's announcement, Thomas Christély, Chief Exe
'/>"/>

SOURCE Silence Therapeutics Plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Silence Therapeutics Provides Corporate and Development Update
2. Silence Therapeutics Signs Collaboration With Mirna Therapeutics to Evaluate Delivery of Novel microRNA Therapeutics
3. Silence Therapeutics Issued Japanese Patent Covering its Core RNA Interference (RNAi) Technology
4. Silence Therapeutics Lead RNA Interference Therapeutic Prevents Spread of Cancer to Lungs
5. Silence Therapeutics Receives Comprehensive Protection for RNAi Structural Modification Technology in Single European Patent
6. Silence Therapeutics Partner Quark Signs Exclusive Option Agreement With Novartis for Development and Commercialisation of QPI-1002
7. Silence Therapeutics Expands RNAi Structural Modification IP Portfolio With Issuance of New U.S. Patent
8. Silence Therapeutics Issued Novel RNAi Patent Covering High-Value Cancer Target in United States
9. Silence Therapeutics Appoints New Vice President of Research
10. Silence Therapeutics to Present at 12th Annual BIO CEO & Investor Conference
11. National Ovarian Cancer Coalition and PureOlogy to Host First Annual NOCC and PureOlogys Walk to Break the Silence on Ovarian Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... July 10, 2014 Terascala, the industry ... that Alan Swahn, a former vice president of product ... as vice president of marketing. Terascala’s software when combined ... NetApp create the highest performance and most reliable solutions ... to guide Terascala’s channel expansion and broaden its product ...
(Date:7/10/2014)... Montreal, QC (PRWEB) July 10, 2014 ... comfort and convenience. This rejuvenating device now comes with a ... that develops over time. , The new cup is thinner ... This design works to target rough, thin and uneven surfaces ... original firm cup for a stimulating treatment on areas such ...
(Date:7/10/2014)... -- Kainos Capital, a firm specializing in acquiring and managing ... acquired the Slim-Fast brand from Unilever. Unilever will retain ... transaction were not disclosed. Slim-Fast is a ... ready-to-drink shakes, powders, bars and snacks to retail customers ... the United Kingdom and Ireland.  ...
(Date:7/10/2014)... 2014 -- According to the International Atomic Energy ... comes from terrorists acquiring sufficient quantities of plutonium ... crude nuclear explosive device. The IAEA also notes ... involved gram-level quantities, which can be challenging to ... a new study appearing this week in the ...
Breaking Biology Technology:Terascala Expands Executive Team 2Terascala Expands Executive Team 3Introducing a New Bonus Treatment Cup for EvoDerma’s NOOME Anti-Aging Motion 2Kainos Capital Acquires Slim-Fast From Unilever 2Sensitive detection method may help impede illicit nuclear trafficking 2
... 26 Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: OXBO) ... sites in Israel for the planned Phase II dose ... Oxycyte is the company,s perfluorocarbon (PFC) therapeutic oxygen carrier. ... planned for Switzerland."Israeli physicians are excited to be able ...
... 26 Cornerstone Therapeutics Inc. (Nasdaq: CRTX ), a specialty ... the respiratory market, today reported financial results for the year ended December ... Full-Year 2008 Net Revenues more than doubled ... , , , ...
... LASIK Surgeons directory service and website at www.TrustedLASIKSurgeons.com ... seeking to improve their vision and find a highly ... attaining 20-20 vision. What sets the Trusted LASIK ... that only those who are among the best in ...
Cached Biology Technology:Oxygen Biotherapeutics, Inc. Adds Oxycyte TBI Clinical Trial Sites in Israel 2Cornerstone Therapeutics Reports Year Ended December 31, 2008 Financial Results 2Cornerstone Therapeutics Reports Year Ended December 31, 2008 Financial Results 3Cornerstone Therapeutics Reports Year Ended December 31, 2008 Financial Results 4Cornerstone Therapeutics Reports Year Ended December 31, 2008 Financial Results 5Cornerstone Therapeutics Reports Year Ended December 31, 2008 Financial Results 6Cornerstone Therapeutics Reports Year Ended December 31, 2008 Financial Results 7Cornerstone Therapeutics Reports Year Ended December 31, 2008 Financial Results 8Cornerstone Therapeutics Reports Year Ended December 31, 2008 Financial Results 9Cornerstone Therapeutics Reports Year Ended December 31, 2008 Financial Results 10Cornerstone Therapeutics Reports Year Ended December 31, 2008 Financial Results 11Cornerstone Therapeutics Reports Year Ended December 31, 2008 Financial Results 12Trusted LASIK Surgeons Welcomes LASIK Expert William Mathers, M.D. of the Casey Vision Correction Center in Portland, Oregon, to Its LASIK Directory 2Trusted LASIK Surgeons Welcomes LASIK Expert William Mathers, M.D. of the Casey Vision Correction Center in Portland, Oregon, to Its LASIK Directory 3Trusted LASIK Surgeons Welcomes LASIK Expert William Mathers, M.D. of the Casey Vision Correction Center in Portland, Oregon, to Its LASIK Directory 4Trusted LASIK Surgeons Welcomes LASIK Expert William Mathers, M.D. of the Casey Vision Correction Center in Portland, Oregon, to Its LASIK Directory 5Trusted LASIK Surgeons Welcomes LASIK Expert William Mathers, M.D. of the Casey Vision Correction Center in Portland, Oregon, to Its LASIK Directory 6Trusted LASIK Surgeons Welcomes LASIK Expert William Mathers, M.D. of the Casey Vision Correction Center in Portland, Oregon, to Its LASIK Directory 7Trusted LASIK Surgeons Welcomes LASIK Expert William Mathers, M.D. of the Casey Vision Correction Center in Portland, Oregon, to Its LASIK Directory 8
(Date:7/11/2014)... explored two different ways that allow unprecedented experimental ... formation of oxygen molecules in photosynthesis. The two ... Nature Communications . , "The new knowledge ... water oxidation, which are key components for building ... solar energy in fuels like hydrogen, ethanol or ...
(Date:7/11/2014)... under the normal circumstances, astrocytes participate in ... environment, and exhibit therapeutic and repairing effects ... studies have found that nerve cells differentiated ... have reduced viability, which produces influences on ... Kailuan General Hospital, Hebei United University, China ...
(Date:7/10/2014)... Santa Fe, Albuquerque, and other major cities in New ... with treated municipal wastewater rather than precious potable water ... than 40% of all golf courses receive treated effluent. ... , Additionally, golf courses and homeowners alike fertilize ... in fertilizer is nitrate. A New Mexico State University ...
Breaking Biology News(10 mins):Molecular snapshots of oxygen formation in photosynthesis 2'Tailored' water -- the latest in lawn care 2
... of grapes (Vitis vinifera) chiefly to make wine, is an ... from the Neolithic and Early Bronze Ages. We have a ... grape harvest leading to the concept of terroir (the range ... nature of the grapes themselves has been less well understood ...
... CRUZ, CA-- No human can survive longer than a few ... gulps of air. Our brains need a constant supply of ... seals, animals that dive and hunt under the Antarctic sea ... minutes, and remain active and mentally alert the whole time. ...
... HOUSTON (Dec. 18, 2007)Researchers at The University of ... between genes regulating glucose metabolism and spina bifida. The ... from parents and their children with that birth defect. ... dozen genes that take part in glucose metabolism to ...
Cached Biology News:Plant geneticists find veritas in vino 2Plant geneticists find veritas in vino 3Why diving marine mammals resist brain damage from low oxygen 2Why diving marine mammals resist brain damage from low oxygen 3Why diving marine mammals resist brain damage from low oxygen 4UT-Houston's Northrup and colleagues uncover genetic link to spina bifida 2
...
MOUSE ANTI BOVINE WC1:FITC Immunogen: Bovine lymphocytes...
... kit contains the basic components required for ... natural and recombinant Feline IL-10 in cell ... sufficient materials to run ELISAs on approximately ... conditions are met: The assay is ...
Request Info...
Biology Products: